TERZİ DEMİRSOY, E. Et Al. 2019. Serum Soluble Programme Death-1 and Programme Death- Ligand 1 Identify Multiple Myeloma Patients: Serum sPDL-1 May Be a Prognostic Marker. Eurasian Journal of Medical Investigation , vol.3, no.1 , 23-31.

TERZİ DEMİRSOY, E., BİRTAŞ ATEŞOĞLU, E., TARKUN, P., MEHTAP, Ö., GEDÜK, A., & HACİHANİFİOĞLU, A., (2019). Serum Soluble Programme Death-1 and Programme Death- Ligand 1 Identify Multiple Myeloma Patients: Serum sPDL-1 May Be a Prognostic Marker. Eurasian Journal of Medical Investigation , vol.3, no.1, 23-31.

TERZİ DEMİRSOY, ESRA Et Al. "Serum Soluble Programme Death-1 and Programme Death- Ligand 1 Identify Multiple Myeloma Patients: Serum sPDL-1 May Be a Prognostic Marker," Eurasian Journal of Medical Investigation , vol.3, no.1, 23-31, 2019

TERZİ DEMİRSOY, ESRA T. Et Al. "Serum Soluble Programme Death-1 and Programme Death- Ligand 1 Identify Multiple Myeloma Patients: Serum sPDL-1 May Be a Prognostic Marker." Eurasian Journal of Medical Investigation , vol.3, no.1, pp.23-31, 2019

TERZİ DEMİRSOY, E. Et Al. (2019) . "Serum Soluble Programme Death-1 and Programme Death- Ligand 1 Identify Multiple Myeloma Patients: Serum sPDL-1 May Be a Prognostic Marker." Eurasian Journal of Medical Investigation , vol.3, no.1, pp.23-31.

@article{article, author={ESRA TERZİ DEMİRSOY Et Al. }, title={Serum Soluble Programme Death-1 and Programme Death- Ligand 1 Identify Multiple Myeloma Patients: Serum sPDL-1 May Be a Prognostic Marker}, journal={Eurasian Journal of Medical Investigation}, year=2019, pages={23-31} }